The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Transitioning bispecifics into community care for myeloma: recently published guidelines
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the growing use of bispecific antibodies in multiple myeloma (MM) and the need to transition their administration from academic centers to community care settings, highlighting recently published guidelines to inform and support this shift. Prof. Mohty highlights the importance of patient selection, education, and strict standard operating procedures (SOPs) for managing complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections in the outpatient setting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
